From Crisis to Blueprint: How Australian Burns Pioneer Fiona Wood Is Engineering the Future of Scarless Healing

The history of regenerative medicine is often told as a series of laboratory “eureka” moments. But for Professor Fiona Wood, the pioneer behind the revolutionary “spray-on skin,” these breakthroughs were never destined for the sterile isolation of a petri dish; they were forged in the high-pressure environment of the operating theater where the “traditional” simply wasn’t enough. It was this realization—that clinical urgency must dictate the pace of scientific discovery—that transformed her from a surgeon into an architect of infrastructure. “I just got hooked by the whole concept that we had to be able to do better with respect to scarring,” Wood recalls. “Scarring is more than skin deep. It influences the way you move, how you interact—it’s pervasive.”

Today, as Director of the Burns Service of Western Australia, Professor Wood is moving the conversation from simple skin replacement to systemic regeneration. Her journey provides a master-level case study in how translational science, scrappy engineering, and patient-centered thinking must intersect to drive real-world impact.

The Listening Crisis: A key moment in Wood’s journey was realizing that clinical science often fails when it doesn’t listen to the environment. From her work with indigenous communities, she learned that healing isn’t just about cells—it’s about designing systems that work where resources don’t exist, proving that “cultural fit” is just as vital as biological compatibility. Image: GeneOnline

When Science Outpaces the Patient: The Need for Speed

In the early 1980s, the “state of the art” for major burns was Cultured Epithelial Autograft (CEA) sheets. While revolutionary in theory, the process was a logistical nightmare. Skin samples were flown from Australia to specialized labs in Boston or Melbourne, grown for three weeks, and then flown back.

For a patient with 60% burns, three weeks is an eternity. It is a period defined by extreme infection risk, fluid loss, and the slow, agonizing formation of thick, restrictive scar tissue. Wood’s first mission was to break this timeline. By 1993, she and scientist Marie Stoner had hacked the process down to 10 days. However, the real breakthrough was biological: they realized that mature, laboratory-grown skin sheets were fragile and prone to blistering.

The “Mouth Freshener” Engineering Hack

The pivot was counterintuitive: Use younger cells. Wood realized that immature cells—harvested at just five days—were more “sticky” and robust. They were “anchors” that wanted to attach to the body. The challenge then shifted from biology to delivery: How do you apply a delicate “soup” of cells evenly across a massive, irregular wound?

“We went to the art store, the pharmacy, the anesthetic trolley—everything that could spray,” Wood says. They eventually discovered that a nozzle from an Italian mouth freshener, clipped onto a 5ml syringe, provided 90% cell viability with zero dead space. This scrappy, high-stakes engineering led to the ReCell kit, effectively putting a “tissue engineering lab in a box” that could be used at the patient’s bedside in just 20 minutes.

“We use the body as the tissue culture flask. By reducing the time to heal, we reduce the pain, the scarring, and the cost.”

The “Blueprint” vs. The “Scaffold”: A Shift in Philosophy

As regenerative medicine moves into the era of 3D bioprinting and organoids, Wood offers a grounding correction to a common industry misconception: the idea that we need to build “chunky,” permanent physical replacements for tissue.

“It is a misconception that a scaffold takes the place of skin,” Wood explains. “What we need isn’t a scaffold so much as a blueprint.”

According to Wood, a synthetic scaffold is merely a temporary structure that the body eventually breaks down. The real magic happens when the architecture and chemistry of that scaffold trigger the cells to produce their own tissue.

• The In-Situ Revolution: Wood argues that the body is the ultimate bioreactor. By spraying cells directly onto a well-prepared wound, the orchestration of cytokines and chemistry is far more “nuanced” than anything currently achievable in a sterile GMP laboratory.
• Beyond Skin: We cannot regenerate skin in isolation. Wood’s current research focuses on the “drivers” of regeneration—how the nervous system and bone marrow respond to injury. If the nerve supply to an axolotl’s tail is damaged, it won’t grow back. Wood is looking for those same systemic triggers in humans to facilitate a regenerative rather than a fibrotic (scarring) response.

The Hard Path to Adoption: Lessons in Tenacity

Translating a breakthrough into a global standard of care is rarely linear. Wood’s experience offers a roadmap for navigating the “Valley of Death” between a clinical idea and market access.

The Regulatory “Dossier”

Wood admits that early in her career, the team moved so fast to save lives that they skipped some traditional steps, such as early-stage animal work, because the treatment had already become their clinical standard of care. This created a hurdle when seeking FDA approval later.

“Do it right, do it once,” she advises. “If you cut corners, you will have to come back and do it again. It is false economy.” She urges innovators to view regulatory bodies not as barriers, but as collaborators. “Talk to the regulators early. They don’t want to tell you at the end that you should have done X, Y, and Z. They want to help you design a trial they can actually accept.”

Economic Sustainability & Global Access

In an era of million-dollar therapies, Wood is a vocal advocate for “learning from the complex to make it simple.” “Our system is not sustainable,” she warns. To ensure global equity, we must cleave off the essential parts of a complex therapy to make it manufacturable at a lower cost. If a therapy is only available in a high-tech center in Perth, it has failed the majority of the world’s population.

Leadership Under Constraint: From Bali to the “Bottle Spray”

Professor Wood is perhaps most famously known for her leadership during the 2002 Bali bombings, where she led the response for victims flown to Perth. That experience solidified her view on innovation under constraint.

“The smart money is thinking about it beforehand,” she says regarding disaster planning. Resilience isn’t just about “toughing it out”; it’s about having a flexible system in place. When she visited indigenous communities in Northern Australia to teach burn care, she realized they didn’t have running water for the required 20-minute cooling.

Instead of giving up, she listened to the community. They developed a system using plastic spray bottles to mist the burn—a culturally and environmentally appropriate solution that achieved the same cooling effect with a fraction of the water.

The Future: The Wood Methodology for Lasting Impact

Professor Wood’s career suggests that scientific discovery is only the first step. To move from a breakthrough to a backbone of medical care, leaders must master several overlooked factors:

• Prioritize Point-of-Care Engineering: Success isn’t just about the cell; it’s about the delivery. By designing systems like ReCell that function in the OR, you eliminate the massive costs and risks associated with clean-room transport.
• The Systemic Integration Strategy: True regeneration isn’t a “patch.” Wood emphasizes interrogating the bone marrow and the nervous system alongside the wound. This shift in focus ensures that we aren’t just covering a wound, but facilitating a whole-body curative response.
• The Simplicity Directive for Global Scale: High-fidelity medicine must be made low-complexity for the user. By “cleaving the complex into the essential,” innovators can drive down the Cost of Goods (COGS), making life-saving technology accessible to third-world environments and not just elite Western hospitals.
• The “Responsibility Agenda” for Sustainability: We must address the “swamping” of the health system. Wood advocates for empowering patients with simple, effective knowledge—like the 20-minute cooling rule—to reduce the severity of injuries before they reach the hospital. This systemic efficiency frees up funding for high-end regenerative interventions when they are truly needed.
• Proactive Regulatory Engagement: Don’t treat the FDA as a “final boss.” Early, transparent communication ensures your clinical trial design matches the “permitters'” requirements, significantly de-risking the path to market.

“It’s our responsibility as the custodians of today to push the barriers of knowledge, to leave something behind us that is better than yesterday,” Wood concludes. Her message to the next generation of biotech leaders is clear: The road to scarless healing is long and hard, but for the patient waiting on the table, it is a road we must finish building together.

GeneOnline In Conversation: Professor Fiona Wood details the transition from emergency “spray-on” solutions to a systemic roadmap for global regenerative medicine. This exclusive look explores how the “custodians of today” must bridge the gap between clinical breakthroughs and sustainable health infrastructure. Image: GeneOnline

Author

Bernice Lottering

Related Post

Manufacturing & Logistics

Translational Frontiers in Regenerative Medicine: Navigating Clinical Bottlenecks and Commercial Scale for Advanced Cell Therapies

2026-07-20

Interviews

Japan Advances Clinical Translation of Extracellular Vesicle Therapies Through GMP-Grade EV Programs

2026-05-25

go prime

South Korea’s Clonell Unveils “Ultimate Regenerative Medicine Platform,” Promising Patient-Specific Stem Cells to Tackle Immune Rejection

2026-01-07